Recombinant AAV vectors for enhanced expression of authentic IgG

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Fuchs, Sebastian P ^a,b   Martinez Navio, José M ^a   Gao, Guangping ^c   Desrosiers, Ronald C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FURIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; PARVOVIRUS VECTOR; RECOMBINANT DNA;

ADENO ASSOCIATED VIRUS 2; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; FOOT AND MOUTH DISEASE VIRUS; HUMAN; HUMAN CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS RECOMBINANT; WOODCHUCK HEPATITIS VIRUS; DEPENDOPARVOVIRUS; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEK293 CELL LINE; METABOLISM; STAINING; TRANSGENE;

DEPENDOVIRUS; DNA, RECOMBINANT; GENETIC VECTORS; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; STAINING AND LABELING; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84976898455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0158009     Document Type: Article

References (52)

1. Samulski RJ, Muzyczka N (2014) AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. Annual Review of Virology, Vol 1 1: : 427-451.
2. Ura T, Okuda K, Shimada M (2014) Developments in Viral Vector-Based Vaccines. Vaccines 2: 624. doi: 10.3390/vaccines2030624 PMID: 26344749
3. Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M (2013) Viral vectors: a look back and ahead on gene transfer technology. New Microbiol 36: 1-22. PMID: 23435812
4. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, et al. (1995) T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 270: 475-480. PMID: 7570001
5. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419. PMID: 14564000
6. Kotterman MA, Schaffer DV (2014) Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet 15: 445-451. doi: 10.1038/nrg3742 PMID: 24840552
7. Wang D, Zhong L, Nahid MA, Gao G (2014) The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv 11: 345-364. doi: 10.1517/17425247.2014.871258 PMID: 24386892
8. Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, et al. (1996) A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 7: 1145-1159. PMID: 8773517
9. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr., Mingozzi F, et al. (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248. doi: 10.1056/ NEJMoa0802315 PMID: 18441370
10. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, et al. (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365. doi: 10.1056/ NEJMoa1108046 PMID: 22149959
11. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, et al. (2012) Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 20: 443-455. doi: 10.1038/ mt.2011.237 PMID: 22068425
12. MacLaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, et al. (2014) Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 383: 1129-1137. doi: 10.1016/S0140-6736(13)62117-0 PMID: 24439297
13. Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, et al. (2013) Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 20: 361-369. doi: 10.1038/gt.2012.43 PMID: 22717743
14. Scott LJ (2015) Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency. Drugs 75: 175-182. doi: 10.1007/s40265-014-0339-9 PMID: 25559420
15. Bryant LM, Christopher DM, Giles AR, Hinderer C, Rodriguez JL, et al. (2013) Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev 24: 55-64. doi: 10.1089/humc.2013.087 PMID: 23808604
16. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, et al. (2009) Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 15: 901-906. doi: 10.1038/nm.1967 PMID: 19448633
17. Fuchs SP, Martinez-Navio JM, Piatak M Jr., Lifson JD, Gao G, et al. (2015) AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity. PLoS Pathog 11: e1005090. doi: 10.1371/journal.ppat.1005090 PMID: 26248318
18. Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, et al. (2015) AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519: 87-91. doi: 10.1038/ nature14264 PMID: 25707797
19. Saunders KO, Wang L, Joyce MG, Yang ZY, Balazs AB, et al. (2015) Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects non-human primates from mucosal simian-human immunodeficiency virus infection. J Virol.
20. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, et al. (2012) Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481: 81-84.
21. Martinez-Navio JM, Fuchs SP, Pedreno-Lopez S, Rakasz EG, Gao G, et al. (2015) Host Anti-antibody Responses Following AAV-Mediated Delivery of Antibodies against HIV and SIV in Rhesus Monkeys. Mol Ther.
22. McCarty DM (2008) Self-complementary AAV vectors; advances and applications. Mol Ther 16: 1648-1656. doi: 10.1038/mt.2008.171 PMID: 18682697
23. McCarty DM, Monahan PE, Samulski RJ (2001) Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8: 1248-1254. PMID: 11509958
24. Wu J, Zhao W, Zhong L, Han Z, Li B, et al. (2007) Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of rep proteins in vector purity. Hum Gene Ther 18: 171-182. PMID: 17328683
25. West AP Jr., Galimidi RP, Gnanapragasam PN, Bjorkman PJ (2012) Single-chain Fv-based anti-HIV proteins: potential and limitations. J Virol 86: 195-202. doi: 10.1128/JVI.05848-11 PMID: 22013046
26. Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR (2002) Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 76: 8769-8775. PMID: 12163597
27. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T (2000) IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 1: 376-382. PMID: 10933956
28. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, et al. (2005) Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23: 584-590. PMID: 15834403
29. Fang J, Yi S, Simmons A, Tu GH, Nguyen M, et al. (2007) An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther 15: 1153-1159. PMID: 17375065
30. Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, et al. (2008) Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther 15: 1411-1423. doi: 10.1038/gt.2008.90 PMID: 18496571
31. Cai B, Pan H, Flynn GC (2011) C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo. Biotechnol Bioeng 108: 404-412. doi: 10.1002/bit.22933 PMID: 20830675
32. Zufferey R, Donello JE, Trono D, Hope TJ (1999) Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 73: 2886-2892. PMID: 10074136
33. Choi JH, Yu NK, Baek GC, Bakes J, Seo D, et al. (2014) Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons. Mol Brain 7: 17. doi: 10.1186/1756-6606-7-17 PMID: 24618276
34. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, et al. (2008) Next generation of adenoassociated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 105: 7827-7832. doi: 10.1073/pnas.0802866105 PMID: 18511559
35. Markusic DM, Herzog RW, Aslanidi GV, Hoffman BE, Li B, et al. (2010) High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther 18: 2048-2056. doi: 10.1038/mt.2010.172 PMID: 20736929
36. Hakim CH, Yue Y, Shin JH, Williams RR, Zhang K, et al. (2014) Systemic gene transfer reveals distinctive muscle transduction profile of tyrosine mutant AAV-1, -6, and -9 in neonatal dogs. Mol Ther Methods Clin Dev 1: 14002. PMID: 25105153
37. Qiao C, Zhang W, Yuan Z, Shin JH, Li J, et al. (2010) Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther 21: 1343-1348. doi: 10.1089/hum.2010.003 PMID: 20497037
38. Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, et al. (2011) Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther 22: 1239-1247. doi: 10.1089/hum.2011.053 PMID: 21609134
39. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, et al. (2014) Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371: 1994-2004. doi: 10.1056/ NEJMoa1407309 PMID: 25409372
40. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, et al. (2005) Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105: 1424-1430. PMID: 15507527
41. Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, et al. (2009) Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A 106: 16363-16368. doi: 10.1073/pnas.0904514106 PMID: 19706466
42. Gao GP, Lu Y, Sun X, Johnston J, Calcedo R, et al. (2006) High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes. J Virol 80: 6192-6194. PMID: 16731960
43. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, et al. (2003) Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10: 2112-2118. PMID: 14625565
44. Wang Z, Ma HI, Li J, Sun L, Zhang J, et al. (2003) Rapid and highly efficient transduction by doublestranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 10: 2105-2111. PMID: 14625564
45. Wu Z, Sun J, Zhang T, Yin C, Yin F, et al. (2008) Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 16: 280-289. PMID: 18059373
46. Kingsman SM, Mitrophanous K, Olsen JC (2005) Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Ther 12: 3-4. PMID: 15510172
47. Schambach A, Bohne J, Baum C, Hermann FG, Egerer L, et al. (2006) Woodchuck hepatitis virus posttranscriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther 13: 641-645. PMID: 16355114
48. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347. PMID: 16474400
49. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, et al. (2007) CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13: 419-422. PMID: 17369837
50. Johnson WE, Sanford H, Schwall L, Burton DR, Parren PW, et al. (2003) Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol 77: 9993-10003. PMID: 12941910
51. Mueller C, Ratner D, Zhong L, Esteves-Sena M, Gao G (2012) Production and discovery of novel recombinant adeno-associated viral vectors. Curr Protoc Microbiol Chapter 14: Unit14D 11.
52. Goncalves MA (2005) Adeno-associated virus: from defective virus to effective vector. Virol J 2: 43. PMID: 15877812